US Robot Surgery Boom Lifts Intuitive's Outlook

Intuitive Surgical raises its 2026 procedure growth forecast after Q1 revenue of $2.77B, driven by surging US utilization

14 May 2026

American operating rooms are embracing robotic surgery at the fastest clip in years, and the company that dominates the field just raised its bets. Intuitive Surgical posted Q1 2026 revenue of $2.77 billion, up 23 percent year over year, then lifted its full-year da Vinci procedure growth forecast to 13.5–15.5%. The quarter beat analyst expectations across the board, and shares jumped nearly 8% the next morning.

The numbers tell a story of deepening adoption, not just expansion. US procedure volumes rose 16%, with global growth hitting 17%. More telling, after-hours cases surged 31% domestically, suggesting hospitals are squeezing more value from the robots they already own rather than simply buying new ones.

Of the 431 da Vinci systems placed during the quarter, 232 were the next-generation da Vinci 5, bringing its installed base to 1,500 units. Those newer machines are running 4% hotter than the older Xi models they're replacing.

The surgical mix is shifting too. General surgery and acute care are pulling volume that urology once owned, with CEO Dave Rosa pointing to appendectomies as a key growth driver. Robotic-assisted procedures now account for an estimated 15% of US surgeries, a share that keeps climbing as clinical indications widen and reimbursement frameworks catch up.

Not everything is working in Intuitive's favor. GLP-1 weight-loss drugs have crushed bariatric volumes to under 3% of US robotic cases. International results lagged on pricing pressure in China and sluggish recovery in Japan. A Q1 phishing incident also exposed some customer and employee data, though the company said the financial impact was negligible.

Competition is heating up as well. Medtronic and CMR Surgical are entering the US market with lower-cost, portable platforms designed to bring robotics to hospitals that couldn't previously afford them. But more players in the space tends to accelerate adoption curves, generate richer outcome data, and feed an innovation cycle that lifts the whole sector.

For hospital leaders weighing the investment, the calculus is getting simpler. Robotic surgery has crossed a threshold where the systems built today will define operating room performance for the next decade. Those who move early will carry utilization and data advantages that latecomers will struggle to match.